Abstract Atherosclerosis is the most life-threatening pathology worldwide. Its major clinical complications, stroke, myocardial infarction, and heart failure, are on the rise in many regions of the world-despite considerable progress in understanding cause, progression, and consequences of atherosclerosis.
Monocytes-precursors of most macrophages and dendritic cells
It has been shown over the last decades by a plethora of experiments that macrophages-tissue-resident cells of myeloid origin that figure in a variety of physiological and pathological conditions-are the main effector cells in the atherosclerotic plaque [13, 14] . In a simplified view, macrophages represent promiscuous phagocytes that can engulf a plethora of pathogens and debris in a variety of tissues, including modified and native lipids in the vessel wall [15] . While fulfilling their role as the main scavengers of the innate immune system, macrophages transform, become lipid-laden foam cells and drive the inflammatory milieu in the atherogenic vessel wall by secretion of cytokines and chemokines, and their interaction with other immune cells in the plaque [16] , although this view has recently been challenged [17] . It has been proposed that lesional macrophage burden and phenotype may correlate with clinical outcome. This as yet unproven hypothesis has led to the terms stable (thick cap, few inflammatory cells) and unstable (macrophage and lipid-rich plaque) plaque [18] . Unstable plaques are more likely to give rise to lifethreatening complications, such as myocardial infarction and stroke [19] . Destabilization of the atherosclerotic plaque is thought to occur as result of matrix metalloproteinases that are secreted by macrophages and other cells and can eventually destruct the plaque's extracellular matrix [20, 21] .
Originally, it was believed that macrophages solely arise from monocytes [22] . However, many tissues are seeded by primitive hematopoietic precursor cells prior to the emergence of definitive hematopoiesis [22, 23] and self-renew in tissues [24] . Consistent with this, macrophages are found in the aorta even in the absence of atherosclerosis [7] . However, monocyte invasion, in particular of the pro-inflammatory, CCR2
? Ly6C high (Gr-1 ? ) monocyte subset occurs through all stages of disease [25, 26] , an observation that has led to the assumption that plaque macrophages originate from monocytes [27, 28] . A number of findings supports that circulating monocytes contribute to plaque macrophages: Numbers of monocytes in the periphery are elevated in atherosclerosis-prone ApoE -/-mice and correlate with disease severity [25] [26] [27] . Homing studies using latex beads to label monocyte populations [26] suggest that both Ly-6C hi and Ly-6C lo monocytes access atherosclerotic lesions, but monocyte transendothelial migration and differentiation to macrophages have not been observed directly. Recent development of multiphoton intravital microscopy in atherosclerotic arteries [29] holds promise that this may become possible soon. This would establish whether monocytes enter from the lumen as is currently believed, or whether vasa vasorum is an additional source of monocytes.
Novel mechanisms that explain monocytosis during atherosclerosis have recently been identified: Some of them are located in the bone marrow, where hyperglycemia [30] or modulation of reverse cholesterol transport in hematopoietic stem cells (HSPCs) [31] regulates monocyte generation and their efflux in the periphery. Interestingly, activation of the sympathetic nervous tone by pain, anxiety, stress, and circadian events can drive adrenergic signaling in the bone marrow niche and generation of Ly6C high proinflammatory monocytes [32] [33] [34] . Notably, monocyte progenitors can also populate alternative niches, such as the spleen, and can be released into circulation [35, 36] . Taken together, monocytes infiltrating into the plaque are one origin of plaque macrophages.
The plaque macrophage-a stem cell within the artery?
The dogma that every monocyte turns into a macrophage has been challenged in the last years. After myocardial infarction, the heart muscle is infiltrated by macrophages [35] . Interestingly, fate mapping of macrophages residing in the myocardium demonstrated that proliferation occurred in macrophages that preferentially take up bacteria, suggesting a role in immunesurveillance [50] . On the contrary, in an inflammatory milieu during myocardial infarction, the proliferating fraction of macrophages died or disappeared from the heart, while newly recruited macrophages dominated. These data unveil that the function of proliferating macrophages in heart and atheromata may be distinct [51] .
It is clear from these results that macrophages in the plaque and in the heart share properties with self-renewing stem cells, although their lineage potential may be very narrow. Tissue-resident macrophages have clearly been shown to self-renew in the peritoneum, liver (KupfferCells), brain (microglia), and the skin (Langerhans cells). These cells originate from primitive hematopoietic cells in the yolk sac and are placed in tissues during embryogenesis [23, 24, [52] [53] [54] [55] [56] . Such macrophages are also found in the heart and their contribution to tissue regeneration, antigen sampling, and efferocytosis, rather than to inflammation has been proposed [57, 58] . Whether such yolk sac-derived macrophages are also present in the arterial wall and whether they proliferate locally remains to be tested.
Transdifferentiation-an alternative source of plaque macrophages?
The different origins of plaque macrophages may be expanded by one old idea that has gained new attention in the last years: that non-myeloid cells may give rise to macrophage-like phagocytes in the plaque. It has been proposed by some studies that vascular smooth muscle cells (VSMCs) can acquire some of the prototypic functions of a macrophage, such as phagocytosis of lipids [59] or phenotypic conversion toward the monocyte lineage [60] . A recent study by Feil et al. has provided new evidence supporting this concept. By employing a genetic fate-mapping approach, the authors suggest that VCMCs residing in the media aortic wall before disease initiation are mobilized into the intima during atherosclerosis [61, 62] . Loss of typical markers of contractile smooth muscle cells (SMC), such as smooth muscle actin (SMA), clonal expansion of the transdifferentiated cells, and expression of myeloid cell markers, such as CD68 and Mac-2, supports the author's hypothesis that SMCs convert in macrophage-like cells. However, despite their phenotypic similarities, it is unclear whether these transdifferentiated cells harbor the same functions as classical plaque macrophages. This will have to be clarified in future studies on gene expression, signaling, and function-an evaluation beyond the expression of some more or less specific myeloid cell markers. In this regard, one recent study proposed that cholesterol signaling skews the phenotype of SMCs toward macrophage-like cells in vitro [63] , which would support a specific role for transdifferentiation in atherosclerotic plaques that are rich of native and modified cholesterol.
The removal of plaque macrophages
In the context of plaque inflammation, it has been proposed that myeloid cells are capable of leaving the plaque and thus facilitate resolution of inflammation [64, 65] . This idea has partially been based on the observation that statins-potent anti-inflammatory drugs developed to lower cholesterol by blocking endogenous cholesterol synthesis-resulted in regression of atherosclerotic plaques in individuals with coronary heart disease [66] . Likewise, inducible reconstitution of ApoE in mice expressing a hydromorphic ApoE allele or that lack ApoE demonstrated diminished atherosclerotic plaques and foam cell content [67, 68] . On the other hand, aggravation of atherosclerosis is associated with increased accumulation of macrophages, which possibly lost their ability to leave the plaque. Notably, in the later stage of disease, but not in the early, the clearance of apoptotic cells-a mechanism referred to as efferocytosis-is impaired [69] . As a result, accumulating apoptotic cells cause secondary necrosis, which in turn aggravates the inflammatory response [70] . Both observations have led to the idea that plaque macrophages are removed from the plaque during regression, a hypothesis also supported by studies demonstrating that macrophages may actively exit some inflammatory compartments by migration, such as from the peritoneal cavity or adipose tissue [71, 72] . Macrophage removal from plaque could occur by active emigration or cell death. To distinguish between these possibilities in the context of atherosclerosis, a surgical model was developed: The atherosclerotic aortic arch was isolated and transplanted into either atherosclerosis-prone ApoE -/-or wildtype mice [65] . When the atherosclerotic aortic arch (marked by an allogeneic marker) was transplanted into wildtype mice, macrophages rapidly disappeared, and their disappearance correlated with the appearance of marker-positive cells in lymph nodes. These findings suggested active migration of plaque macrophages to lymph nodes in an atheroprotective milieu. This effect seemed to be dependent on the chemokine receptor CCR7 and to be modulated by the cholesterol load of macrophages [64, 73] . However, newer studies using bead-tracking techniques optimized for exact quantification of cellular trafficking showed that the egress of macrophages is only a minor factor or even dispensable for the loss of macrophages from the plaque [74] . Instead, lowered monocyte recruitment to the plaque in an environment of normalized circulating lipids-a factor required to induce plaque regression-and a stable, unchanged rate of apoptosis among plaque macrophage were the likely explanations for decreasing macrophage numbers in the plaque during regression. Notably, the authors of this study used a viral transduction by adenovirus to restore ApoE in Beyond vascular inflammation-recent advances in understanding atherosclerosis 3855
an ApoE -/-mouse, a strategy that could bear potential side effects to bias the conclusion of the study [74] . Later studies confirmed that macrophage death is the main contributor to macrophage removal in the peritoneal cavity. In one study, a minor proportion of cells emigrated to lymph nodes [75] . These findings suggest that macrophage death, not egress from the plaque, accompanies plaque regression.
The many faces of plaque macrophages
Macrophages in vivo form two major subsets, M1 and M6 [76, 77] . M1 macrophages kill pathogens by NO produced by iNOS. M2 macrophages promote would heal by converting arginine to ornithine via arginase-1 [177] . The M1 polarization of macrophages is further promoted by IFN-c and such macrophages are known as classically activated [78] . M2 macrophages can be stabilized and further driven to express more arginase-1 by IL-4, also known as alternatively activated macrophages, which express not only arginase-1 but also CD206 (Mannose receptor, MR) [79] . In vitro studies have suggested some possible inducers and signaling molecules predisposing for either one of the phenotypes, including TLR ligands, IFN-c, GM-CSF (M1), or IL-4 and some fatty acid species (M2) [80] . However, the in vivo cues are largely unknown. Genetic predisposition of the host, tissue-derived cues, and pathogen-derived molecules like TLR ligands is suspected modifiers of macrophage phenotype [77] . NFjB and NLRP3 pathways are dominant in M1 macrophages [81] and PPARc and Nr4a1 in M2 macrophages [82] . The distinct transcriptome of M1 and M2 macrophages includes IL-12 and Tumor Necrosis Factor (TNF)-a in M1, which supports a T H 1 adaptive immune response, and IL-10 in M2, which supports a T H 2 adaptive immune response. One view holds that M1 and M2 macrophages dominate in the atherosclerotic plaque at different stages. The few available in vivo studies suggest that M1, M2, and other macrophages exist in plaques side-by-side [83] .
Many in vitro studies have suggested that macrophage polarization could be more complex. Some plaque macrophages show reduced expression of the scavenger receptor CD163 for the hemoglobin-haptoglobin complex, which is characteristic of M4 macrophages induced by the chemokine CXCL4 [84, 85] . A fourth macrophage phenotype can be identified by its expression of the anti-inflammatory enzyme heme oxygenase (HOX) -1, a unique phenotype, induced by oxidized phospholipids, called Mox [80, 83] . In vitro, some macrophages express high levels of IL-10 and have been termed regulatory macrophages (Mreg) [86, 87] , but their in vivo relevance for atherosclerosis remains unclear. The description of macrophage phenotypes in mouse or human atherosclerosis remains incomplete [13, 88, 89] . Although there is no requirement for adaptive immune cytokines to induce M1 or M2 polarization [90] , it is reasonable to speculate that immune cells, such as T or B cells, help regulate the macrophage phenotype by cytokine expression, e.g., by secretion of the T H 2 cytokine IL-4 to induce a protective M2 phenotype.
Certain macrophage phenotypes may predispose toward distinct clinical outcomes: Some newer studies show that macrophages with specific functional repertoires localize within distinct parts of the plaque, an effect likely mediated by the site-specific microenvironment: While M1 macrophages predominate in rupture-prone regions of human plaques, M2 macrophages seem to inhabit the adventitia. Notably, areas of plaque hemorrhage show elevated expression of the hemoglobin receptor CD163 (Mhem phenotype) [91] -while the fibrous cap of atheromata, as well as foam cells, showed no clear predisposition for M1/ M2/M4/Mox/Mhem/Mreg phenotypes [90, 92] . Based on these data, it is reasonable to propose that M1 macrophages may predispose for later clinical events, but this remains to be confirmed by clinical studies. Older findings suggested that plaque instability is associated with macrophage-rich lesions showing higher expression of extracellular matrix destabilizing metalloproteinases (MMPs) [20, 93] . Indeed, M1 and M2 polarized macrophages have distinct expression patterns of MMPs: Murine M1-type macrophages show increased gene expression for MMP-13, -14, -25 and lowered expression of MMP-19 and TIMP-2, while M2 macrophages increase expression of MMP-19. A similar pattern was observed in human macrophages [90, 94, 95] . All these data should be considered with caution, because in vitro polarized macrophages are not directly relevant to atherosclerosis.
Besides plaque stability, certain pathologies could theoretically benefit from modulating phenotypic functions of macrophages. For instance, tissue repair-an effector function associated with the M2 phenotype-holds great promise in tissue remodeling after myocardial infarction. Indeed, it was shown that modulation of master transcription factors predisposing for a certain polarization, such as the M1 phenotype driving Interferon regulatory factor (IRF) 5 could represent such a strategy. Silencing IRF5 induced a shift from the inflammatory M1 phenotype toward the M2 phenotype in heart macrophages improving outcome after myocardial infarction [96] . Likewise, genetic inhibition of IRF5 in a combined atherosclerosis/ lupus model was protected from both pathologies, but macrophage-specific function was not tested [97] . These findings are encouraging attempts to understand the impact of polarization-specific transcription factors and distinct functional properties.
The cellular origin of macrophage polarization
Macrophage heterogeneity and function may not only be caused by the microenvironment as new evidence suggests [98, 99] -/-mice lack Ly6C low monocytes [101] , suggesting Nr4a1 is as master transcription factor for the development of this monocyte population. Further studies showed that genetic deficiency of Nr4a1 accelerated atherosclerosis and skewed the phenotype of macrophages toward a pro-inflammatory phenotype with a high expression of TNF-a, nitric oxide, and reduced expression of arginase-1 [82] .
Newer studies suggest that alternatively activated macrophages (just like M1 macrophages) originate from Ly6C high , not Ly6 low monocytes [82] : During myocardial infarction, only Ly6 high monocytes enter the inflamed myocardium, convert to macrophages, and prolong postinfarct healing [102] . Apparently, Nr4a1 is needed to facilitate conversion toward a protective phenotype, an observation based on the finding that Nr4a1 -/-mice developed an inflammatory macrophage phenotype that was associated with worsened outcome in myocardial infarction [82] . This is also suggested by studies on human lesional macrophages, where over-expression of Nr4a1 decreased their pro-inflammatory gene expression in vitro [103] . This new concept is further supported by observations in different pathologies, such as liver injury, which propose that reparative macrophages arise from recruited Ly6 high monocytes [104] . Of course, observations from liver tissue or myocardium cannot directly be translated to the atherosclerotic plaque and future studies will have to clarify the exact origin of these cells. All these findings suggest that Ly-6C hi monocytes may be able to turn into Ly-6C low monocytes, a concept supported by lineage tracking studies [105] .
The need for an integrated model of myeloid cell dynamics in the plaque
How can such new data be integrated into an updated model of macrophage origin and fate in the plaque? Firstly, the role of local proliferation of plaque macrophages versus differentiation from blood monocytes will have to be understood quantitatively. Secondly, macrophage effector function, proliferation, and cell death may depend on the specific microenvironment [98] . Thirdly, different, maybe apparently divergent mechanisms may coexist. In line with this notion, intestinal macrophages not only proliferate in vitro [106] but are also replenished from blood monocytes in vivo [107] and have been shown to be eliminated by apoptosis and migration to lymph nodes [71] . Most likely, different mechanisms exist at the same time, triggered, and amplified by the specific environment. While macrophage accumulation was considered to be in almost linear relationship to monocyte infiltration in the past, future models will have to integrate and quantify the different relative impacts of distinct macrophage progenitors in a spatial and time-dependent view [108] , also incorporating the loss of macrophages by apoptosis or emigration, and possible transdifferentiation from SMC or precursors in the adventitia [109] (Fig. 1) .
The footprints of autoimmunity in atherosclerosis
A large body of recent evidence supports the hypothesis that atherosclerosis is an autoimmune disease, driven by the deposition and modification of lipoproteins in the vessel wall and their detection by specific T cells and antibodies. Particularly, 4 major findings support this hypothesis: (1) T cells infiltrate the aorta, accumulate, and show a restricted repertoire of T cell receptor (TCR), (2) Activation of T cells in the plaque is sustained by interaction with plaque resident antigen-presenting cells (APCs) and requires presentation of specific antigens, (3) In different species, auto-antibodies to lipid antigens and their protein moieties are atheroprotective and associated with better disease outcome, and (4) Outcome of murine atherosclerosis can be modulated by immunizing against some known antigens. The above-mentioned evidence builds the theoretical basis of considering atherosclerosis as autoimmune disease (a comprehensive review is found in Ref. [110] ).
The antigen-specific T cell orchestrates plaque inflammation
About 59 % of cells within advanced human atherosclerotic lesions are macrophages, *38 % of all cells represent CD3
? T cells depending on plaque morphology, while Natural Killer (NK) cells (*1 %) and B cells (*2 %) are only present at minor frequencies [111] . T cells can be detected in all stages of the atherosclerotic plaque [7] and based on their commitment to T helper cell (T H ) lineages, T cells can either act as pro-or anti-inflammatory cells [9] . Notably, most T cells in the plaque are of the T H 1 lineage and express the pro-inflammatory cytokines IFN-c, IL-2, IL-3, TNF, and LT. These cytokines fuel plaque inflammation by stimulating macrophages and other cells resident in the plaque [112] . IFN-c is also present in the human atherosclerotic plaque. Genetic knock-out of IFN-c, its receptor, or of its lineage-defining transcription factor T-bet reduced atherosclerosis in mice [113] [114] [115] , while the contribution of the T H 2 or T H 17 lineage is less important or controversial [116] [117] [118] [119] [120] [121] [122] [123] [124] . high monocytes that transmigrate into the plaque and differentiate (1) . A second monocyte subset, patrolling Ly6C low monocyte is thought to patrol the vessel wall to remove debris and dead endothelial cells. However, Ly6C low monocyte may also contribute to the pool of plaque macrophages by transmigration and differentiation into macrophages. Ly6C low monocytes in the plaque may also originate by conversion from Ly6C high monocytes to give rise to macrophages (2) . Alternatively, it has also been speculated whether plaque macrophages may stem from migrated adventitial macrophages that are possibly derived from the primitive yolk sac during embryogenesis and that may have the potential to self-renew. Depending on the context, macrophages may ingest lipids and turn into foam cells (3) or die (4). It has recently been reported that the pool of plaque macrophages can independently be maintained in the later stages of disease by direct proliferation in situ (5). Besides their differentiation into macrophages, Ly6C high monocytes may transmigrate into the plaque, engulf, and present antigens by MHC-II, before leaving the plaque and migrating into peripheral lymph nodes (6). Likewise, dendritic cells (not shown) and macrophages can migrate into the lymphatic system to present antigens to T cells and initiate an immune response
CD4
? T cells appear to respond to certain antigens in the atherosclerotic plaque: T cells from human and murine plaques show a restricted TCR repertoire, suggesting that those T cells accumulate and proliferate in the plaque, which bear a specific TCR detecting the antigen [125, 126] . Native and modified (ox-) LDL, as well as apoB-100, the main protein component of LDL, represents the most promising candidates for such antigens [127] [128] [129] , but also heat shock proteins (HSPs) and some pathogens were proposed [110, 130] . Notably, T cells isolated from an atherosclerotic aorta specifically recognize oxLDL [129] . Antigen-experienced CD44 hi CD62L-CD4 ? T cells isolated from atherosclerotic mice interacted extensively with dendritic cells in situ in a novel ex vivo imaging approach of explanted aortas [8] . Transfer of a crude T cell suspension responding to oxLDL ex vivo aggravated atherosclerotic disease after adoptive transfer in a model in of scid/ApoE -/-mice [131] . Cytokine expression of autoreactive T cells was dependent on antigen presentation by MHC-II on APCs and binding to TCR [128] , suggesting a specific antigen-driven immune response in the plaque against those autoantigens.
Naturally occurring T-regulatory cells (nT regs ) are gatekeepers of self-tolerance. Although some high affinity self-recognizing T cells are removed in the thymus by negative selection, it is important to recognize that essentially all T cells in an organism not exposed to pathogens are (positively) selected for self-antigens [132, 133] . The effect of Tregs has been extensively tested in the setting of atherosclerotic disease [134] . From a functional point of view, nT regs are considered anti-inflammatory immune cells, classically defined by co-expression of IL-2 receptor, CD25, the forkhead transcription factor (FoxP)-3, and the co-stimulatory molecule CTLA-4 [135] . nT regs are generated in the thymus, selected by self-peptides. Other T cell subsets with potential regulatory function include CD4 T cells that have acquired FoxP3, called induced T-regulatory cells (iT regs ). These cells are induced in the periphery (outside the thymus) and can easily be converted to other T cell subsets, i.e., they are unstable. Other CD4 T cells secrete the anti-inflammatory IL-10 (T r 1 cells) and can act as immune-modulating cells by expressing TGF-b. IL-10 and TGF-b are known to inhibit atherosclerosis in mouse models [136] [137] [138] . In adoptive transfer experiments, a population of CD4
? CD25 ? T cells (containing T regs ) was protected from atherosclerosis [139] . However, newer studies employing a model of T reg depletion by diphtheria toxin receptor under control of the Foxp3 were uninterpretable, because the blood lipid profile of these mice changed significantly [140] . IL-2 antibody complexes are thought to induce T regs and showed beneficial effects in atherosclerosis [141] . These findings are intriguing since T regs are required to limit the pro-inflammatory effects of auto-reactive T cells [132] . Indeed, loss of T regs can induce severe autoimmune disease [139] . A thrilling, but yet unproven presumption based on these and other findings from immunization experiments [142, 143] is that some of the specific T cell clones reactive to ApoB-100 are T regs . Several other important questions remain: Does a natural repertoire of T cells detecting specific antigens exist? Which circumstances may limit or expand this cell subset? Which exact peptide epitopes within the proposed antigens are recognized by specific TCRs on these cells?
Antigen presentation by subsets of macrophages and dendritic cells drives specific immune responses
Antigen presentation is a prerequisite to mature and polarize naïve T cells toward their effector status and the major determinant of antigen specificity in adaptive immunity. To induce a specific immune response against proteins, antigenic peptides must be presented on Major Histocompatibility Complex (MHC)-II (I-A b in C57Bl/6 mice) on antigen-presenting cells (APCs) to allow binding of the T cell receptor (TCR) [144] in the context of CD4. In atherosclerosis, CD4
? T cell activation and secretion of the pro-inflammatory cytokines IFN-c and TNF-a critically depend on interaction and antigen presentation by APCs [8, 145] . Notably, the interaction of APCs and T cells in the atherosclerotic plaque depends on cognate antigens, emphasizing that T cells in the plaque are antigen specific [8] . It is less clear to which extent the interaction with T cells requires specific APCs to maintain or break self-tolerance in the setting of atherosclerosis. However, it has been proposed that distinct lineages of DCs may contribute to or antagonize the autoimmune response in atherosclerosis [146] . Different subtypes of DCs with distinct functional repertoires have been identified in the atherosclerotic plaque. Depending on origin, lineage, and expression of surface markers, at least three different DC subtypes have been defined. All of these show expression of MHC-II and CD11c: Monocyte-derived DCs/macrophages that respond to M-CSF and express CD11b, conventional DCs (cDCs) which can either express CD11b or CD8 or CD103, and PDCA and B220 plasmacytoid DCs (reviewed in Ref. [146] ). It is noteworthy that DCs are already present in the intima of a healthy aorta in mice and humans [147, 148] , although the subsets have not been identified. In advanced plaques, antigen presentation is predominantly carried out by cDCs and macrophages, which show co-expression of CD11b and CD11c and predispose for a T H 1 priming of T cells by secretion of IL-12 and CCL17 (a review summarizing these findings is provided in Ref. [149] ). It has been proposed that the polarization of an immune response-immunogenic or tolerogenic-will be guided during initial antigen presentation [146, 150] . Various mediators can skew the polarization of the immune response by modulating DC activation. While anti-inflammatory signals as IL-10 and TGF-b [151] will skew the response toward a tolerogenic response, IL-6 induces a T H 17, and IL-12 a T H 1 response. In atherosclerosis, disruption of tolerogenic pathways in dendritic cells, for instance, by deletion of the receptor for cytokine fms-like tyrosine kinase 3 ligand (Flt3L), Flt3, can reduce T regs and the net effect is pro-atherogenic [152] . Surprisingly, some signaling pathways involved in DC maturation and T-effector (T eff ) cell generation, such as those initiated by toll-like receptors (TLRs), can result in both, immunogenic and tolerogenic pathways. For instance, genetic deletion of MyD88, a master TLR adapter, resulted in a decrease of both T eff and T reg [153] . Unexpectedly, the decrease of T regs , and not of T effs , determined the outcome in this study with enlarged atherosclerotic lesions and increased recruitment of myeloid cells into the plaque. Moreover, ex vivo pulsing of dendritic cells with ApoB-100 aggravated the immune response with enhanced infiltration of CD4
? T cells, and increased IFN-c and Il-2 in the aorta. DCs that were primed with IL-10 were atheroprotective [154] . However, transferring peptide-pulsed DCs was also atheroprotective without prior cytokine treatment in another study [155] , rendering these results difficult to interpret. Besides monocyte-derived and cDCs, pDCs have recently been tested in an elegant experimental approach, in which the transcription factor Tcf4 was abrogated selectively in CD11c
? cells to reduce pDCs numbers. Mice with such pDC reduction were protected from atherosclerosis and had fewer T H 1 polarized T cells [156] . Taken together, these results clearly indicate that antigen presentation is a fundamental part of atherogenesis and may be accessible to therapeutical modulation. However, the assessment of distinct APC subsets in atherosclerosis has been difficult with respect to its heterogeneity and incomplete tools to inhibit antigen presentation in a disease-specific manner. For instance, diphtheria toxin-guided depletion in CD11c
?
DCs also abrogates CD11c-expressing M1-macrophages [157] . It is not known whether antigen presentation in the vessel wall is crucial for atherosclerosis. It is likely that priming of naïve T cells occurs in peripheral draining lymph nodes and not in the aorta itself [149] . However, there is good evidence that the recall response re-activating antigen-experienced CD4 ? T cells occurs in the atherosclerotic vessel wall [8] (Fig. 2) . Interestingly, cholesterol removal from the plaque also occurs by afferent lymphatics, thus providing a plausible path also for (modified) LDL to reach draining lymph nodes [158] . Whether initial priming and proliferation of T cells followed by tissue homing and second antigen-exposure in non-lymphoid tissue to generate fully polarized effector cells [150] remains to be tested.
Protective humoral autoimmunity in atherosclerosis
T H 1-committed T cells and their response to antigens drive atherosclerotic disease, presumably by expression of proinflammatory and pro-atherogenic mediators. Several observations, however, propose the co-existence of a protective limb of autoimmunity in atherosclerosis: Naturally occurring IgM auto-antibodies, which recognize oxidized low-density lipoprotein (LDL) cholesterol or parts of its main protein moiety, ApoB-100, are inversely correlated with atherosclerotic disease [159] [160] [161] , its complications and risk factors [162] . While IgG antibodies could originate from plasma cells derived from B cells specifically activated by follicular-helper T cells (T FH ), which involves maturation of B cells and Ig-class switch from IgM to IgG [145] , IgM auto-antibodies are expressed by a specific B cell subset, B1a cells, independent of T FH cell help [163] . B1a cells are thought to recognize self-antigens and respond with secretion of IgM antibodies. Those IgM antibodies have been functionally implicated in atheroprotection. Binder et al. demonstrated that immunization of mice with heat-inactivated S. pneumoniae antigen, which shares epitopes with oxidized LDL, increased IgM levels and diminished atherosclerosis [164] . Also, mice with a deficiency in secreting IgM presented increased levels of atherosclerosis [165] . Vice versa, treatment with polyclonal IgM was protected from atherosclerotic disease [166] . Some IgM antibodies can bind to oxLDL and may inhibit uptake of the antigen by macrophages [167, 168] . Fig. 2 Hypothesized mechanisms of T cell-dependent autoimmunity in mice. Generation of T cell clones and antibodies that recognize self-peptides from ApoB-100, the protein moiety of low-density lipoprotein (LDL), have been proposed as main pathways of T celldependent autoimmunity. Antigen-specific, pro-atherogenic T cells are primed in peripheral lymph nodes (lower schematic), but remain incompletely differentiated after first presentation of self-peptides by dendritic cells or Ly6C
? monocytes migrating from the plaque.
(1) A primed T cell may leave the lymph node and home to the plaque to allow for terminal differentiation: In the plaque, presentation by IL-12
? APCs to primed T cells is thought to elicit a pro-atherogenic T H 1 type immune response with the lead cytokines TNF-a and IFN-c.
Conversely, presentation by Flt3
? tolerogenic dendritic cells can induce an atheroprotective response with conversion of the primed T cell into T reg cells and secretion of the anti-inflammatory mediators IL-10 and TGF-b (upper schematic). (2) Alternatively, a primed T cell can differentiate into a follicular-helper T cells (T FH ), which induces generation and secretion of ApoB-100-specific IgG antibodies by plasma cells in the lymph node or tertiary lymphoid organs (lower schematic) Interestingly, IgG antibodies to native and oxidized LDL, are positively correlated with atherosclerotic disease in mice and humans and accumulate in atherosclerotic lesions [169, 170] . Conversely, higher titers of IgM antibodies to oxLDL predict better outcomes [171, 172] . Antibodies directed against peptide epitopes of ApoB-100 are inversely correlated with disease outcome [173] .
A vaccine against atherosclerosis
Following the observation that T cells can specifically recognize autoantigens in the context of atherosclerosis, several vaccination strategies have been proposed in recent years [130] : Immunization of rabbits with MDA-modified LDL, which contains MDA-modified ApoB-100, protected from atherosclerosis [174] , as well as with murine LDL, MDA-modified LDL in mice [175] , and AGE-modified LDL in mice [176] . Additionally, a peptide derived from human ApoB-100, p210 (ApoB-100 3136-3155 ) was found to bind to IgM and IgG antibodies from human sera [177] . Vaccination with p210 protected mice from atherosclerosis and aortic aneurysm formation [178, 179] . While the efficacy of immunization strategies against different antigens, such as naïve and modified LDL, ApoB-100 or peptides derived from ApoB-100, has been demonstrated in various species and animal models [110] (Table 1) , the functional properties of antigen recognition and its exact cellular and functional consequences, as required for the ultimate goal of defining a clinical vaccination strategy in humans, remain enigmatic. For instance, it has been shown that vaccination against some peptides, e.g., p210, conferred atheroprotection in mice, an effect linked to T cell responses in some studies [142, 143, [179] [180] [181] . However, the tested peptide does not bind to mouse MHC-II (I-A b ), thus excluding a CD4
? T cell restricted mode of action. To circumvent these limitations we have recently applied the first systematic screening to determine peptide sequences in mouse ApoB-100 with sufficient affinity to I-A b [182] . Two candidate peptides with high affinity to MHC-II were identified and induced effective CD4
? T cell proliferation. Immunizing against those peptides with a prime in complete Freud's adjuvant (CFA) and three subsequent booster injections in incomplete Freud's adjuvant (IFA) reduced murine atherosclerosis. Mechanistically, we detected more IL-10 transcripts in aortas of immunized mice, suggesting that this cytokine may be causal in atheroprotection [182] . This is supported by other studies showing that T cells with properties of anti-inflammatory T-regulatory cells confer atheroprotection in immunized animals, likely by Il-10 expression [142, 143, 183] .
However, mechanisms of atheroprotection after vaccination are controversial. Depending on antigen, route, and intraperitoneal dose, a plethora of different mechanisms has been suggested (Table 1) . Also, several methodological questions remain unanswered in some studies. Only a few systematic studies have tested and compared appropriate adjuvants, routes, and doses. One study has revealed that the adjuvant alum has atheroprotective effects even when given alone [184] . Also, there is some controversy about whether atheroprotection is carried out by a humoral immune response. The function of plasma cell-derived IgG antibodies against some epitopes after vaccination is not clear. Such antibodies can clear pathogenic antigens [185] , but may be an epiphenomenon since epitopes recognized by such antibodies may not be accessible in atherosclerotic lesions and do not bind LDL [182] . This is consistent with older reports, demonstrating increased IgG antibodies against immunized antigens without protection against atherosclerosis [175] . Also, some newer studies indicate that vaccination with ApoB-100 may raise IgG antibodies to antigens and T H 2 signature immune response without being atheroprotective [186] . Some newer evidence also promoted the concept that over-activation of T FH cells can aggravate atherosclerotic disease, lead by the observation that deletion of to the mouse ortholog of MHC-I HLA-E, Qa-1, resulted in uncontrolled T FH proliferation and generation of enlarged tertiary lymphoid organs (TLOs) in the aorta, which was dependent on the ICOS-ICOSL pathway [187] . Whether this increase was due to enhanced IgG production was not tested. However, recent data also propose that some B cell effector functions in atherosclerosis may be independent of antibody secretion, such as enhanced cytokine secretion [188] [189] [190] , or of triggering a T H 1 response [188] (an excellent review about the complexity of B cell function in atherosclerosis is provided by Ref. [191] ).
Clinical perspective and concluding remarks
A substantial body of evidence identifies inflammatory and immunologic mechanisms as a driving force behind atherosclerosis and its clinical sequelae. Yet clinical treatment strategies to improve outcome are largely limited to inhibition of platelet aggregation and lowering of lipids. While these may enfold additional immune-modulatory, pleiotropic actions resulting in lower clinical event rates [192] and plaque regression [66] , therapies genuinely targeting plaque inflammation and immunology are absent. Two novel strategies, inhibition of interleukin (IL) -1 by a monoclonal antibody called canakinumab [193] and the application of low-dose methotrexate [194] , are currently tested in large clinical trials in a collective of high-risk patients with coronary heart disease. 
